Oruka Therapeutics Announces $180 Million Private Placement
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on chronic skin disease treatments, has secured a $180 million PIPE financing led by Viking Global Investors with participation from multiple prominent healthcare investors.
The financing includes the sale of 10.93 million common shares at $15.00 per share and 1.07 million pre-funded warrants at $14.999 each. Following the transaction, Oruka will have approximately 67.1 million shares outstanding. The deal is expected to close around September 19, 2025.
The proceeds will fund research and development, corporate expenses, and working capital, supporting operations through key clinical trial readouts including ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b in 2027.
Oruka Therapeutics (Nasdaq: ORKA), azienda biofarmaceutica focalizzata sui trattamenti per malattie croniche della pelle, ha assicurato un finanziamento PIPE da 180 milioni di dollari guidato da Viking Global Investors con la partecipazione di diversi importanti investitori del settore sanitario.
La operazione prevede la vendita di 10,93 milioni di azioni ordinarie a 15,00 dollari ciascuna e 1,07 milioni di warrants prefinanziati a 14,999 dollari l'uno. Dopo la transazione, Oruka avrà circa 67,1 milioni di azioni in circolazione. L'accordo dovrebbe chiudere intorno al 19 settembre 2025.
I proventi finanzieranno ricerca e sviluppo, spese societarie e capitale circolante, sostenendo le operazioni fino ai principali esiti di studi clinici tra cui ORKA-002 Fase 2 e ORKA-001 EVERLAST-B Fase 2b nel 2027.
Oruka Therapeutics (Nasdaq: ORKA), una empresa biotecnológica enfocada en tratamientos para enfermedades crónicas de la piel, ha asegurado un financiamiento PIPE por 180 millones de dólares liderado por Viking Global Investors con la participación de varios inversores importantes en el sector sanitario.
La operación incluye la venta de 10,93 millones de acciones comunes a 15,00 dólares cada una y 1,07 millones de warrants prefinanciados a 14,999 dólares cada uno. Tras la transacción, Oruka tendrá aproximadamente 67,1 millones de acciones en circulación. Se espera que el acuerdo cierre alrededor del 19 de septiembre de 2025.
Los fondos financiarán investigación y desarrollo, gastos corporativos y capital de trabajo, apoyando las operaciones hasta los resultados clave de ensayos clínicos, incluyendo ORKA-002 Fase 2 y ORKA-001 EVERLAST-B Fase 2b en 2027.
Oruka Therapeutics (Nasdaq: ORKA), 만성 피부 질환 치료에 집중하는 바이오제약 회사가 Viking Global Investors의 주도와 여러 주요 헬스케어 투자자의 참여로 1억 8000만 달러의 PIPE 자금 조달을 확보했습니다.
거래에는 주당 15.00달러에 1093만 주의 보통주 매출과 각 14.999달러의 107만 주의 프리펀딩 워런트가 포함됩니다. 거래 후 Oruka는 약 6천 7백 10만 주의 발행주식을 보유하게 됩니다. 거래 종결은 2025년 9월 19일경으로 예상됩니다.
조달된 자금은 연구 개발, 회사 비용, 운전자본에 사용되며 ORKA-002 2상과 ORKA-001 EVERLAST-B 2b상과 같은 주요 임상시험의 주요 결과 발표까지 운영을 지원합니다(2027년).
Oruka Therapeutics (Nasdaq : ORKA), une entreprise biotechnologique spécialisée dans les traitements des maladies chroniques de la peau, a obtenu un financement PIPE de 180 millions de dollars dirigé par Viking Global Investors avec la participation de plusieurs investisseurs importants du secteur de la santé.
Le financement comprend la vente de 10,93 millions d’actions ordinaires à 15,00 dollars chacune et de 1,07 million de bons préfinancés à 14,999 dollars chacun. Suite à la transaction, Oruka détiendra environ 67,1 millions d’actions en circulation. La clôture devrait intervenir autour du 19 septembre 2025.
Les fonds serviront à financer la recherche et le développement, les frais d’entreprise et le fonds de roulement, soutenant les opérations jusqu’aux principaux résultats des essais cliniques, notamment ORKA-002 Phase 2 et ORKA-001 EVERLAST-B Phase 2b en 2027.
Oruka Therapeutics (Nasdaq: ORKA), ein Biotechnologieunternehmen, das sich auf Behandlungen chronischer Hauterkrankungen spezialisiert hat, hat eine PIPE-Finanzierung über 180 Millionen US-Dollar unter Führung von Viking Global Investors mit Beteiligung mehrerer prominenter Gesundheitsinvestoren gesichert.
Die Finanzierung umfasst den Verkauf von 10,93 Millionen Stammaktien zu je 15,00 USD und 1,07 Millionen vorfinanzierten Warrants zu je 14,999 USD. Nach der Transaktion wird Oruka voraussichtlich rund 67,1 Millionen Aktien ausstehen haben. Der Abschluss der Transaktion wird voraussichtlich am 19. September 2025 erfolgen.
Die Erlöse werden in Forschung und Entwicklung, Unternehmensaufwendungen und Working Capital investiert, um den Betrieb bis zu wichtigen klinischen Studienergebnissen zu unterstützen, darunter ORKA-002 Phase 2 und ORKA-001 EVERLAST-B Phase 2b im Jahr 2027.
Oruka Therapeutics (ناسداك: ORKA)، وهي شركة تكنولوجيا حيوية تركز على علاجات أمراض الجلد المزمنة، حصلت على تمويل PIPE بقيمة 180 مليون دولار بقيادة Viking Global Investors بمشاركة عدة مستثمرين رفيعي المستوى في قطاع الرعاية الصحية.
يشمل التمويل بيع 10.93 مليون سهم عادي بسعر 15.00 دولار للسهم و1.07 مليون سند مموّل مقدماً بسعر 14.999 دولار لكل واحد. عقب الصفقة، ستبقى لدى أوركا حوالي 67.1 مليون سهم قائم. من المتوقع إغلاق الصفقة حوالي 19 سبتمبر 2025.
ستستخدم العائدات في البحث والتطوير، ونفقات الشركة، ورأس المال العامل، لدعم العمليات حتى قراءة نتائج التجارب السريرية الرئيسية بما في ذلك ORKA-002 المرحلة 2 وORKA-001 EVERLAST-B المرحلة 2b في 2027.
Oruka Therapeutics（纳斯达克：ORKA），一家专注于慢性皮肤病治疗的生物科技公司，已在 Viking Global Investors 主导、多位知名医疗投资者参与下完成<1.8亿美元的PIPE融资。
此次融资包括以每股15.00美元出售1092.93万股普通股以及以14.999美元/股的1.07百万张预设权证。本次交易后，Oruka 将拥有约6710万股在外流通股。交易预计在2025年9月19日左右完成。
募集资金将用于研发、公司开支和营运资金，支持在2027年前的关键临床试验读数，包括ORKA-002 2期和ORKA-001 EVERLAST-B 2b期。
- None.
- Significant dilution with 12 million new shares being issued
- Share price set at $15.00 represents current market valuation constraints
- Additional future financing may be needed beyond 2027 trial readouts
Insights
Oruka secures $180M from elite investors, extending runway through critical 2027 clinical data readouts for skin disease treatments.
Oruka Therapeutics (ORKA) has secured a substantial
This capital infusion significantly strengthens Oruka's financial position, extending its operational runway through at least 2027 - crucially covering the completion of two key clinical programs: the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b trials for chronic skin diseases, including plaque psoriasis. The extended cash runway through these important data readouts substantially de-risks the company's development timeline.
The caliber of participating investors is particularly noteworthy, with the round attracting elite biotech-focused funds including Perceptive Advisors, Blackstone, Citadel's Surveyor Capital, and Cormorant Asset Management. This high-quality investor syndicate signals strong institutional confidence in Oruka's therapeutic approach and validates its clinical development strategy in the dermatology space.
With approximately 67.1 million shares outstanding post-financing, Oruka has effectively managed dilution while securing sufficient capital to advance its pipeline. The proceeds are earmarked for research and development activities, suggesting continued investment in its novel biologics platform targeting chronic skin conditions - a therapeutic area with substantial market potential given the prevalence and recurring nature of diseases like psoriasis.
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately
Pursuant to the terms of the securities purchase agreement, Oruka is selling an aggregate of (i) 10,933,405 shares of its common stock (“Common Stock”) at a purchase price of
The Company intends to use the net proceeds from the PIPE financing, together with the Company’s existing cash, cash equivalents, and marketable securities, to provide financing for research and development, general corporate expenses, and working capital needs. The Company expects that its cash will fund its operations for at least one year following the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in 2027.
Jefferies, TD Cowen, Guggenheim Securities and LifeSci Capital are acting as joint placement agents for the PIPE financing.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the securities purchase agreement, Oruka and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of Common Stock and the Common Stock issuable upon exercise of the pre-funded warrants, in each case sold in the PIPE financing.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Oruka and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Oruka’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the intended use of proceeds from the PIPE financing, Oruka’s cash sufficiency and runway, including as it relates to the anticipated timing of clinical trials and data readouts, the expected timing of closing of the PIPE financing and the completion of the PIPE financing, and Oruka’s business plans. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “potential,” “pipeline,” “can,” “target,” “believe,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, market conditions and the satisfaction of closing conditions, as well as those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Oruka.
Investor Contact:
Alan Lada
(650) 606-7911
alan.lada@orukatx.com
FAQ
How much funding did Oruka Therapeutics (ORKA) raise in its September 2025 PIPE financing?
What will Oruka Therapeutics use the $180 million PIPE proceeds for?
Who were the major investors in Oruka's September 2025 PIPE financing?
How many shares did Oruka Therapeutics (ORKA) issue in the PIPE financing?
How long will Oruka's cash runway extend following the PIPE financing?
